Ironwood Pharmaceuticals (IRWD) Shares are Up 4.85%

Ironwood Pharmaceuticals (IRWD) : Traders are bullish on Ironwood Pharmaceuticals (IRWD) as it has outperformed the S&P 500 by a margin of 9.21% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.21%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.85% in the last 1 week, and is up 16.59% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Ironwood Pharmaceuticals (NASDAQ:IRWD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $13.92 and $13.90 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $14.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $14.27, notching a gain of 3.11% for the day. The total traded volume was 828,105 . The stock had closed at $13.84 on the previous day.


The stock has recorded a 20-day Moving Average of 9.08% and the 50-Day Moving Average is 13.76%. Ironwood Pharmaceuticals, Inc. is up 31.64% in the last 3-month period. Year-to-Date the stock performance stands at 23.12%.

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *